(VIANEWS) – Tidewater (TDW), Brookfield (BAM), Great Elm Capital Corp. (GECC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tidewater (TDW)
66.5% sales growth and 5.52% return on equity
Tidewater Inc., together with its subsidiaries, provides offshore support vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels worldwide. It provides services in support of offshore crude oil and natural gas exploration, field development, and production, as well as windfarm development and maintenance, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, and seismic and subsea support; geotechnical survey support for windfarm construction; and various specialized services, such as pipe and cable laying. The company operates anchor handling towing supply vessels, platform supply vessels, crew boats, utility vessels, and offshore tugs. The company serves oil and natural gas exploration, field development, and production companies; mid-sized and smaller independent exploration and production companies; foreign government-owned or government-controlled organizations, and other related companies; drilling contractors; and other companies, such as offshore construction, windfarm development, diving, and well stimulation companies. Tidewater Inc. was incorporated in 1956 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Tidewater has a trailing twelve months EPS of $1.06.
PE Ratio
Tidewater has a trailing twelve months price to earnings ratio of 64.08. Meaning, the purchaser of the share is investing $64.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.52%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 530% and 640%, respectively.
2. Brookfield (BAM)
22.1% sales growth and 20.43% return on equity
Brookfield Asset Management Ltd. provides alternative asset management services. Its renewable power and transition business includes the ownership, operation, and development of hydroelectric, wind, solar, and energy transition power generating assets. The company's infrastructure business engages in the ownership, operation, and development of utilities, transport, midstream, data and sustainable resource assets. In addition, its private equity business offers business, infrastructure, and industrials services; and real estate business, which includes core investments, and transitional and development investments. Further, the company engages in the residential development business including homebuilding, and condominium and land development. The company was incorporated in 2022 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Brookfield has a trailing twelve months EPS of $0.05.
PE Ratio
Brookfield has a trailing twelve months price to earnings ratio of 671. Meaning, the purchaser of the share is investing $671 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.43%.
Moving Average
Brookfield’s value is higher than its 50-day moving average of $33.19 and above its 200-day moving average of $32.77.
Previous days news about Brookfield(BAM)
- According to GlobeNewsWire on Monday, 13 November, "Barrick’s corporate office is located at Brookfield Place, TD Canada Trust Tower, Suite 3700, 161 Bay Street, P.O. Box 212, Toronto, Ontario M5J 2S1. "
- According to Zacks on Wednesday, 15 November, "Most of the fund’s holdings were in companies like TransDigm Group, Inc (5.5%), Copart, Inc. (5.2%) and Brookfield Corp (4.7%) as of Jul 31, 2023."
3. Great Elm Capital Corp. (GECC)
21.4% sales growth and 14.3% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $1.71.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 5.59. Meaning, the purchaser of the share is investing $5.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.3%.
Volume
Today’s last reported volume for Great Elm Capital Corp. is 5095 which is 80.08% below its average volume of 25585.
Sales Growth
Great Elm Capital Corp.’s sales growth is 48% for the present quarter and 21.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 53.8%, now sitting on 33.99M for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 14.64%.
4. Arthur J. Gallagher & Co. (AJG)
16.4% sales growth and 11.92% return on equity
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to businesses and organizations worldwide. It operates in Brokerage and Risk Management segments. The Brokerage segment offers retail and wholesale insurance and reinsurance brokerage services; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; and acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverages to underwriting enterprises. This segment also performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers services in the areas of insurance and reinsurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent brokers and consultants. It serves commercial, industrial, public, religious, and not-for-profit entities, as well as underwriting enterprises. The company was founded in 1927 and is headquartered in Rolling Meadows, Illinois.
Earnings Per Share
As for profitability, Arthur J. Gallagher & Co. has a trailing twelve months EPS of $5.2.
PE Ratio
Arthur J. Gallagher & Co. has a trailing twelve months price to earnings ratio of 46.48. Meaning, the purchaser of the share is investing $46.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.92%.
5. United Therapeutics Corporation (UTHR)
16.2% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.13.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.38. Meaning, the purchaser of the share is investing $12.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $224.43 at 00:22 EST, way below its 52-week high of $283.09 and above its 52-week low of $204.44.
Volume
Today’s last reported volume for United Therapeutics Corporation is 352227 which is 18.88% above its average volume of 296276.
6. Yelp (YELP)
9.4% sales growth and 12.76% return on equity
Yelp Inc. operates a platform that connects consumers with local businesses in the United States and internationally. The company's platform covers various local business categories, including restaurants, shopping, beauty and fitness, health, and other categories, as well as home, local, auto, professional, pets, events, real estate, and financial services. It provides free and paid advertising products to businesses, which include cost-per-click search advertising and multi-location Ad products, as well as enables businesses to deliver targeted search advertising to local audiences; and business listing page products. The company also offers other services comprising Yelp Guest Manager, a subscription-based suite of front-of-house management tools for restaurants, nightlife and certain other venues, which include online reservations, a waitlist management solution that allows consumers to check wait times and join waitlists remotely as well as through hostless kiosks, and seating and server rotation management tools; Yelp Knowledge program that offers business owners local analytics and insights through access to its historical data and other proprietary content; and Yelp Fusion, which offers free and paid access to content and data for consumer-facing enterprise use through publicly available APIs. In addition, it provides content licensing, as well as allows third-party data providers to update and manage business listing information on behalf of businesses. Further, the company offers its products directly through its sales force; indirectly through partners; and online through its website and business app, as well as non-advertising partner arrangements. It has partnership with Grubhub for providing consumers with a service to place food orders for pickup and delivery. The company was incorporated in 2004 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Yelp has a trailing twelve months EPS of $1.26.
PE Ratio
Yelp has a trailing twelve months price to earnings ratio of 36.32. Meaning, the purchaser of the share is investing $36.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.76%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Yelp’s EBITDA is 2.05.
Yearly Top and Bottom Value
Yelp’s stock is valued at $45.76 at 00:22 EST, below its 52-week high of $47.59 and way higher than its 52-week low of $25.30.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 169.2% and 50%, respectively.
Volume
Today’s last reported volume for Yelp is 271205 which is 53.95% below its average volume of 588950.
7. Ingersoll (IR)
8.3% sales growth and 7.57% return on equity
Ingersoll Rand Inc. provides various mission-critical air, fluid, energy, specialty vehicle, and medical technologies in the United States, Europe, the Middle East, India, Africa, and the Asia Pacific. It operates through two segments, Industrial Technologies and Services, and Precision and Science Technologies. The Industrial Technologies and Services segment designs, manufactures, markets, and services air and gas compression, vacuum, and blower products; fluid transfer equipment and loading systems; and power tools and lifting equipment, including associated aftermarket parts, consumables, air treatment equipment, controls, other accessories, and services under the under the Ingersoll Rand, Gardner Denver, Nash, CompAir, Elmo Rietschle, Robuschi, Emco Wheaton, and Runtech Systems brands. The Precision and Science Technologies segment designs, manufactures, and markets diaphragm, piston, water-powered, peristaltic, gear, vane, progressive cavity, and syringe pumps; and gas boosters, hydrogen compression systems, automated liquid handling systems, odorant injection systems, controls, software, and other related components and accessories for liquid and gas dosing, transfer, dispensing, compression, sampling, pressure management, and flow control in specialized or critical applications under the Air Dimensions, Albin, ARO, Dosatron, Haskel, LMI, Maximus, Milton Roy, MP, Oberdorfer, Seepex, Thomas, Welch, Williams, YZ, and Zinnser Analytic brand names. This segment's products are used in medical, life sciences, industrial manufacturing, water and waste water, chemical processing, energy, food and beverage, agriculture, and other markets. It sells through an integrated network of direct sales representatives and independent distributors. The company was formerly known as Gardner Denver Holdings, Inc. and changed its name to Ingersoll Rand Inc. in March 2020. Ingersoll Rand Inc. was founded in 1859 and is headquartered in Davidson, North Carolina.
Earnings Per Share
As for profitability, Ingersoll has a trailing twelve months EPS of $1.84.
PE Ratio
Ingersoll has a trailing twelve months price to earnings ratio of 37.94. Meaning, the purchaser of the share is investing $37.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.57%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.1%, now sitting on 6.46B for the twelve trailing months.
8. AMETEK (AME)
5.9% sales growth and 16.43% return on equity
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets.Its EMG segment offers engineered electrical connectors and electronics packaging to protect sensitive devices and mission-critical electronics; precision motion control products for data storage, medical devices, business equipment, automation, and other applications; high-purity powdered metals, strips and foils, specialty clad metals, and metal matrix composites; motor-blower systems and heat exchangers for use in thermal management, military, commercial aircraft, and military ground vehicles; and motors for use in commercial appliances, fitness equipment, food and beverage machines, hydraulic pumps, and industrial blowers. This segment also operates a network of aviation maintenance, repair, and overhaul facilities. In addition, the company offers clinical and educational communication solutions. AMETEK, Inc. was incorporated in 1930 and is headquartered in Berwyn, Pennsylvania.
Earnings Per Share
As for profitability, AMETEK has a trailing twelve months EPS of $5.52.
PE Ratio
AMETEK has a trailing twelve months price to earnings ratio of 27.89. Meaning, the purchaser of the share is investing $27.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.43%.
Moving Average
AMETEK’s worth is above its 50-day moving average of $151.06 and above its 200-day moving average of $148.22.
